Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression.The study was conducted in partnership with Uppsala University Hospital.Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of c ...